AARHUS, Denmark – Today, CLC bio is happy to announce that the positive growth rates of the recent years are continuing.

Not only are sales still going up, but in 2010 CLC bio also increased the number of employees by more than 25% – a trend planned to continue in 2011.

CEO at CLC bio, Thomas Knudsen, states, “After realizing an impressive sales increase of 130% in 2009, we kept pushing ahead with a year over year increase of a very respectable 64% in 2010. Last year we were above 10 Million USD for the first time, but more importantly, we have now very nearly 1000 unique organzations as customers and we’re profitable with a positive cash flow. This continued growth will allow us to accelerate our investments in product development and expand our market coverage for the benefit of our valued customers and collaborators.”

“We have now all the Top 10 pharma companies in the world as our customers, which is a clear indication that we’re leveraging the premier commercial high-throughput sequencing data analysis solutions for organizations working with genomics analyses” adds Director of Communications at CLC bio, Lasse Görlitz, and continues, “One of the more successful additions to our product portfolio has been our enterprise offerings that include hardware, where we have experienced a dramatic increase in sales to the pharmaceutical industry, agricultural biotechnology, human biotechnology, as well as government and academic research institutes.”

CLC bio is a privately owned company, primarily funded by local investors and successfully built without venture capital since January 2005.

About CLC bio

https://www.clcbio.com/about